In recent months, the company has been further expanding its GMP pilot plant with a second suite equipped with 10,000 L reactors
Indena has announced it will present at DCAT 2022, discussing recent improvements to its CDMO services, including the expansion of its existing GMP pilot plant for APIs, the doubling of its kilo lab LK2 for OEB 5 products and the installation of a 250 L industrial hydrogenator.
In recent months, the company has been further expanding its GMP pilot plant with a second suite equipped with 10,000 L reactors, expanding its offering at intermediate scale. The company says its goal is to offer customers the ability to run synthetic processes at a range of scales and conditions for natural, semisynthetic and fully synthetic molecules.
The company has more than doubled the capacity of its kilo lab LK2 for OEB 5 products. The lab will also now be capable of running larger-scale reactions, up to 60 L. With this expansion, the company can offer different capacities for products at its highest containment level (OEL 20 ng/m3 or OEB5).
Finally, the company has begun work on the installation of a 250 L hydrogenator, which it says will be ready by 2022. Together with its existing 20 L hydrogenator, this device will allow the company to meet market demand with more flexibility.
“Indena is a full service provider and a reliable partner for the cGMP contract development and production of active and highly potent pharmaceutical ingredients,” said Pietro Allegrini, R&D Director of Indena. “Our reliability is rooted in one hundred year history and in our longstanding leadership in the field of botanical active ingredients. On the other hand, since years we’ve been focusing to the HPAPI production, introducing equipment and soft skills devoted to such specific field in our plants. That allows us to effectively support leading pharmaceutical and biotech companies in creating successful product, for the benefit of end users”.